批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2005/01/07 |
ORIG-1(原始申请) |
Approval |
Type 5 - New Formulation or New Manufacturer |
STANDARD
;Orphan
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2020/08/25 |
SUPPL-47(补充) |
Approval |
Labeling-Package Insert,Labeling-Patient Package Insert |
STANDARD
|
|
|
| 2019/12/06 |
SUPPL-46(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
PRIORITY
|
|
|
| 2018/08/16 |
SUPPL-45(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2016/03/24 |
SUPPL-43(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/11/02 |
SUPPL-42(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/07/21 |
SUPPL-41(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
| 2014/12/11 |
SUPPL-40(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2014/04/28 |
SUPPL-39(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2013/10/30 |
SUPPL-38(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2013/09/06 |
SUPPL-37(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
;Orphan
|
|
|
| 2013/06/07 |
SUPPL-36(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2012/12/10 |
SUPPL-33(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2012/10/11 |
SUPPL-31(补充) |
Approval |
Efficacy-New Indication |
STANDARD
|
|
|
| 2012/09/28 |
SUPPL-35(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2012/09/28 |
SUPPL-34(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2011/12/23 |
SUPPL-29(补充) |
Approval |
Labeling-Package Insert |
UNKNOWN
|
|
|
| 2011/12/23 |
SUPPL-26(补充) |
Approval |
Labeling |
UNKNOWN
|
|
|
| 2011/12/23 |
SUPPL-25(补充) |
Approval |
Labeling-Package Insert |
UNKNOWN
|
|
|
| 2009/06/26 |
SUPPL-22(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2008/07/01 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
| 2007/02/15 |
SUPPL-10(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
UNKNOWN
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:PACLITAXEL; 剂型/给药途径:POWDER;INTRAVENOUS; 规格:100MG/VIAL; 治疗等效代码:AB<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 021660 |
001 |
NDA |
ABRAXANE |
PACLITAXEL |
POWDER;INTRAVENOUS |
100MG/VIAL |
Prescription |
Yes |
Yes |
AB |
2005/01/07
|
BRISTOL-MYERS |
| 211875 |
001 |
NDA |
PACLITAXEL |
PACLITAXEL |
POWDER;INTRAVENOUS |
100MG/VIAL |
Prescription |
Yes |
Yes |
AB |
2022/07/27
|
AM REGENT |
| 216338 |
001 |
NDA |
PACLITAXEL |
PACLITAXEL |
POWDER;INTRAVENOUS |
100MG/VIAL |
Prescription |
Yes |
Yes |
AB |
2023/05/11
|
TEVA PHARMS INC |
| 212700 |
001 |
ANDA |
PACLITAXEL |
PACLITAXEL |
POWDER;INTRAVENOUS |
100MG/VIAL |
Prescription |
No |
No |
AB |
2024/10/08
|
HENGRUI PHARMA |
| 209657 |
001 |
ANDA |
PACLITAXEL |
PACLITAXEL |
POWDER;INTRAVENOUS |
100MG/VIAL |
Prescription |
No |
No |
AB |
2025/04/10
|
CIPLA |
| 216355 |
001 |
ANDA |
PACLITAXEL |
PACLITAXEL |
POWDER;INTRAVENOUS |
100MG/VIAL |
Prescription |
No |
No |
AB |
2025/05/15
|
SHUANGCHENG |
| 217877 |
001 |
ANDA |
PACLITAXEL |
PACLITAXEL |
POWDER;INTRAVENOUS |
100MG/VIAL |
Prescription |
No |
No |
AB |
2025/08/19
|
MYLAN |